Go Back

Infography: planning an oncology study with eCOA/ePRO

21 February 2017

The FDA has provided guidance on methodology to be used for developing and using PRO in oncology drug development programmes, and has emphasized the increased importance on patient input in clinical trials. In addition to QoL, many PRO questionnaires are used to assess complementary areas in oncology study, including: disease related symptoms (pain or fatigue), physical/social/emotional aspects, symptomatic adverse events, and satisfaction with the care provided.

Using eCOA for oncology trials can be particularly challenging because of the range of therapeutic approaches. Key components should be taken into consideration in your oncology study to ensure the success of eCOA implementation.

To download the infography, click here:

Capture d’écran 2017-02-21 à 14.31.14



  • 15 May
    OCT Europe - 15th & 16th May – Barcelona, Spain - Booth #75 Schedule a meeting with Kayentis OCT Europe Barcelona
  • 06 June
    PCMG Annual Conference - June 6 - 8th June – Valletta, Malta - Schedule a meeting with Kayentis
  • 12 June
    OCT London - June 12th & 13th, London, UK - Schedule a meeting with Kayentis OCT London 2018
  • 24 June
    DIA 2018 Annual Meeting - June 24th-28th - Boston, MA - Booth #724 Schedule a meeting with Kayentis DIA Boston June 2018
  • Follow us

    Download our brochure